{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:28:51Z","timestamp":1791084531793,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by hormonal and metabolic abnormalities. Mitsugumin-53 (MG53), a multifunctional E3 ubiquitin ligase, is implicated in insulin signaling and oxidative stress regulation, yet its role in PCOS remains unclear. This study aimed to investigate serum MG53 levels in women with PCOS and explore their associations with hormonal, metabolic, and ovarian parameters. In this case\u2013control study, 64 women with PCOS and 64 healthy controls with comparable age were enrolled. Serum MG53 concentrations were measured by ELISA. Associations between MG53 and continuous variables were assessed using Spearman\u2019s rank correlation. Independent determinants of MG53 were evaluated using multivariable linear regression (including age and BMI as covariates), and diagnostic performance for PCOS was assessed using receiver operating characteristic (ROC) analysis. Serum MG53 concentrations were lower in women with PCOS than in controls (median [IQR]: 124.4 [104.25\u2013202.15] vs. 206.4 [131.63\u2013316.58] pg\/mL;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001). MG53 correlated positively with sex hormone\u2013binding globulin (SHBG) (\u03c1\u2009=\u20090.274,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002) and inversely with ovarian follicle count (\u03c1\u2009=\u2009\u2009\u2212\u20090.223,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.011). In multivariable analysis, SHBG remained an independent positive determinant of MG53, whereas hirsutism and follicle count were independent negative predictors. MG53 demonstrated modest discrimination for PCOS (AUC\u2009=\u20090.667, 95% CI 0.569\u20130.762), with 57.8% sensitivity and 75.0% specificity at an exploratory cut-off of 131.1\u00a0pg\/mL. Serum MG53 is reduced in PCOS and is associated with SHBG and features related to androgen excess and ovarian morphology. These cross-sectional findings support MG53 as a candidate biomarker reflecting metabolic\u2013reproductive associations in PCOS; however, its diagnostic performance is modest and requires external validation.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Trial registration<\/jats:italic>\n                    Prospectively registered on ClinicalTrials.gov (NCT07094776) as an observational study.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-48800-z","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T09:07:41Z","timestamp":1776071261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Decreased serum MG53 levels are associated with SHBG and androgen excess in women with polycystic ovary syndrome"],"prefix":"10.1038","volume":"16","author":[{"given":"Enes Serhat","family":"Co\u015fkun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Ketenci","family":"Gencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcleyman","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilhan","family":"Nurlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Havva Bet\u00fcl","family":"Bacak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Kumbasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6zde Y\u0131ld\u0131r\u0131m","family":"Timur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ecenur","family":"\u00c7eliko\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eevval","family":"\u00dcnl\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Tun\u00e7\u00e7a\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"G\u00fcven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"2","key":"48800_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/AOG.0000000000002698","volume":"132","author":"R Azziz","year":"2018","unstructured":"Azziz, R. Polycystic ovary syndrome. Obstet. Gynecol. 132(2), 321\u2013336 (2018).","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"48800_CR2","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1093\/ejendo\/lvad096","volume":"189","author":"HJ Teede","year":"2023","unstructured":"Teede, H. J. et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur. J. Endocrinol. 189(2), G43\u2013G64 (2023).","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"48800_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1210\/er.2015-1018","volume":"36","author":"DA Dumesic","year":"2015","unstructured":"Dumesic, D. A. et al. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr. Rev. 36(5), 487\u2013525 (2015).","journal-title":"Endocr. Rev."},{"issue":"4","key":"48800_CR4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.steroids.2011.12.003","volume":"77","author":"F Gonz\u00e1lez","year":"2012","unstructured":"Gonz\u00e1lez, F. Inflammation in polycystic ovary syndrome: Underpinning of insulin resistance and ovarian dysfunction. Steroids 77(4), 300\u2013305 (2012).","journal-title":"Steroids"},{"issue":"7437","key":"48800_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nature11834","volume":"494","author":"R Song","year":"2013","unstructured":"Song, R. et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature 494(7437), 375\u2013379 (2013).","journal-title":"Nature"},{"issue":"7","key":"48800_CR6","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1161\/CIRCULATIONAHA.118.037216","volume":"139","author":"H-K Wu","year":"2019","unstructured":"Wu, H.-K. et al. Glucose-sensitive myokine\/cardiokine MG53 regulates systemic insulin response and metabolic homeostasis. Circulation 139(7), 901\u2013914 (2019).","journal-title":"Circulation"},{"key":"48800_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110916","volume":"204","author":"C Bianchi","year":"2023","unstructured":"Bianchi, C. et al. MG53 does not mark cardiovascular risk and all-cause mortality in subjects with type 2 diabetes: A prospective, observational study. Diabetes Res. Clin. Pract. 204, 110916 (2023).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"48800_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61040582","volume":"61","author":"S Yan\u0131k \u00c7olak","year":"2025","unstructured":"Yan\u0131k \u00c7olak, S. et al. The relationship between serum MG53 levels and the presence of metabolic syndrome and its components. Medicina 61(4), 582 (2025).","journal-title":"Medicina"},{"key":"48800_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2024.1377025","volume":"15","author":"Y-F Wang","year":"2024","unstructured":"Wang, Y.-F., An, Z.-Y., Li, J.-W., Dong, Z.-K. & Jin, W.-L. MG53\/TRIM72: Multi-organ repair protein and beyond. Front. Physiol. 15, 1377025 (2024).","journal-title":"Front. Physiol."},{"key":"48800_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102357","volume":"54","author":"K Gumpper-Fedus","year":"2022","unstructured":"Gumpper-Fedus, K. et al. MG53 preserves mitochondrial integrity of cardiomyocytes during ischemia reperfusion-induced oxidative stress. Redox Biol. 54, 102357 (2022).","journal-title":"Redox Biol."},{"key":"48800_CR11","unstructured":"Liggett, M. R., Wang, B., Dawood, Z. S., Zhang, M., Jin, G., Ho, J. W., Taylor, M. E., White, V., Pla, I., Sanchez, A. Treatment with MG53 ameliorates traumatic brain injury-associated acute kidney injury. J. Trauma and Acute Care Surg. 10.1097 (2023)."},{"issue":"3","key":"48800_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/biom15030418","volume":"15","author":"HR Bulgart","year":"2025","unstructured":"Bulgart, H. R., Lopez Perez, M. A. & Weisleder, N. Enhancing membrane repair using recombinant MG53\/TRIM72 (rhMG53) reduces neurotoxicity in Alzheimer\u2019s Disease models. Biomolecules 15(3), 418 (2025).","journal-title":"Biomolecules"},{"issue":"1","key":"48800_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.13247","volume":"33","author":"L Peng","year":"2025","unstructured":"Peng, L. et al. Suppression of TRIM72\u2010mediated endoplasmic reticulum stress facilitates FOXM1 promotion of diabetic ulcer healing. Wound Repair Regen. 33(1), e13247 (2025).","journal-title":"Wound Repair Regen."},{"issue":"11","key":"48800_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012747","volume":"20","author":"W Tan","year":"2024","unstructured":"Tan, W. et al. Trim72 is a major host factor protecting against lethal Candida albicans infection. PLoS Pathog. 20(11), e1012747 (2024).","journal-title":"PLoS Pathog."},{"issue":"1","key":"48800_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13019-024-03210-y","volume":"20","author":"Z Li","year":"2025","unstructured":"Li, Z., Li, K. & Zhao, J. YTHDF2 mediates the protective effects of MG53 on myocardial infarction injury via recognizing the m6A modification of MG53. J. Cardiothorac. Surg. 20(1), 121 (2025).","journal-title":"J. Cardiothorac. Surg."},{"issue":"4","key":"48800_CR16","first-page":"505","volume":"68","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y., Wu, H.-K., Lv, F.-X. & Xiao, R.-P. MG53 is a double-edged sword for human diseases. Sheng Li Xue Bao 68(4), 505\u2013516 (2016).","journal-title":"Sheng Li Xue Bao"},{"key":"48800_CR17","doi-asserted-by":"publisher","DOI":"10.2478\/aite-2025-0022","author":"L Zhang","year":"2025","unstructured":"Zhang, L., Chen, P., Han, P., Fu, H. & Sun, B. Overexpression of Annexin A1 inhibits pyroptosis and improves dry eye signs by regulating the TRIM72\/Nrf2\/HO-1 signaling pathway. Arch. Immunol. Ther. Exp. https:\/\/doi.org\/10.2478\/aite-2025-0022 (2025).","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"48800_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1389329","volume":"11","author":"E Shamsan","year":"2024","unstructured":"Shamsan, E. et al. The role of PI3k\/AKT signaling pathway in attenuating liver fibrosis: A comprehensive review. Front. Med. 11, 1389329 (2024).","journal-title":"Front. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48800-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48800-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48800-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:23:32Z","timestamp":1779287012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48800-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["48800"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-48800-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8007485\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the Gaziosmanpa\u015fa Training and Research Hospital Ethics Committee (approval date: June 18, 2025; approval number: 25). Written informed consent was obtained from all participants prior to enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"15753"}}